Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Papa bought shares worth $5m
View:
Post by grammadux on Jun 13, 2016 8:02am

Papa bought shares worth $5m

Now he is in the game, could break resistance at $25.50 today

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) CEO Joseph Papa bought 202,000 shares at $24.48 per share Monday morning. The purchase came after key events last week.

  • Tuesday: Reported Q1 Adj. EPS $1.27 vs $1.37 Est., Sales $2.4B vs $2.38B Est.
  • Tuesday: Cut FY16 Sales Outlook from $11B-$11.2B to $9.9B-$10.1B vs $10.9B Est., Adj. EPS $8.50-$9.50 to $6.60-$7 vs $8.47 Est.
  • Tuesday: Cut FY16 Adj. EBITDA from $5.6B-$5.8B to $4.8B-$4.95B
  • Wednesday: S&P said stable rating outlook, financial performance will improve to levels that would suggest higher ratings in the future. Removed from CreditWatch.
  • Thursday: Valeant mulled sale of Egyptian drug maker Amoun to accelerate debt reduction.

At time of writing, Valeant traded at $25.14, up 4.14 percent in Monday's pre-market session.


Read more at https://www.stockhouse.com/news/press-releases/2016/06/13/valeant-ceo-joe-papa-trades-5-million-of-shares#wGQem4qobLh4mx06.99
Comment by Lostinmarket123 on Jun 13, 2016 9:38am
Papa has to buy as per contract .. He needs to spend 5 million ... But look at his buying price ... He made sure he buys cheaper than his investors... He will buy more and I am sure he wants them further cheap doesn't matter what happens to investor ... He will in any case get the golden handshake when he leaves ...
VALEANT PHARMACEUTICALS INTL INC